Precigen Inc. PT receives Investment Bank Analyst Rating Update
JMP Securities analyst Jason Butler reiterated a Buy rating on Precigen (NASDAQ:PGEN) on Friday, setting a price target of $13, which is approximately 160.52% above the present...
JMP Securities analyst Jason Butler reiterated a Buy rating on Precigen (NASDAQ:PGEN) on Tuesday, setting a price target of $13, which is approximately 145.75% above the present...
1. Arena Pharmaceuticals Arena Pharmaceuticals (NASDAQ:ARNA) broke out, and I put a swing on it on Tuesday. I like the look when it broke through resistance, and then it kept...
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.
|Average||12.200 (+463.51% Upside)|
|No. of Analysts||5|